Author:
Kroh U.,Knoch M.,Lennartz H.
Publisher
Springer Berlin Heidelberg
Reference21 articles.
1. Addonizio VP, Macarak EJ, Niewiarowski S, Colman RW, Edmunds LH Jr. (1979) Preservation of human platelets with Prostaglandin E1 during in vitro Simulation of cardio-pulmonary bypass. Circ Res 44: 350–357
2. Baldamus CA (1986) Hämofiltration als Behandlungsmethode des akuten Nierenversagens. Anästh Intensivmed 27: 87–90
3. Bischoff K, Doehn M (1982) Kontinuierliche pumpengetriebene Ultrafiltration bei Nierenversagen. In: Kramer P (Hrsg) Arterio-venöse Hämofiltration. Vandenhoek Ruprecht, Göttingen Zürich, pp 227–234
4. D’Ambra MN, La Raia PJ, Philbin DM, Watkins WD, Hilgenberg AD, Buckley MJ (1985) Prostaglandin E1. A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg 89: 567–572
5. Dungen JJAM van den, Karliczek GF, Brenken U, Homan JN van der Heide, Wildevuur CRH (1983) The effect of Prostaglandin E1 in patients undergoing clinical cardiopulmonary bypass. Ann Thorac Surg 35: 406–414